Topics:

Prostate Cancer

The Bifunctional Role of Steroid Hormones

This review examines the relevance of a translational framework for studying therapeutic androgens in prostate cancer.

Commentaries:
New Concepts Regarding Testosterone and Prostate Cancer: A Breath of Fresh Air
Friend or Foe: The Bifunctional Role of Steroid Hormones in Prostate Cancer

Prostate Cancer

Patients with limited life expectancies often undergo routine cancer screenings despite evidence that they are unlikely to benefit and may experience harm.

This article reviews the most recent advances in androgen receptor-directed therapies for castration-resistant prostate cancer, and new agents under development.

In the past 5 years we have taken at least 7 steps forward for men with prostate cancer—which hopefully will turn into “one giant leap” in our attempt to convert advanced prostate cancer into a chronic disease.

This is an exciting time for physicians who care for patients with advanced prostate cancer, and more importantly a time of heightened optimism for these men and their families.

It is now well established that castration-resistant disease can be effectively treated using newer androgen receptor-targeting agents such as abiraterone and enzalutamide.

A large European study found that PSA screening reduces prostate cancer deaths, but that these benefits do not outweigh the harms of overtreatment.

How low-risk prostate cancer is managed depends more on the diagnosing physician than the patient’s disease state. Men who were diagnosed by a urologist were more likely to receive a treatment performed by the urologist and more likely to receive a therapy rather than monitoring.

Pages

Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.